More tools:Markets·Screener·Research·Chat

UroGen Pharma Ltd. Ordinary Shares (URGN) Financial Statements

UroGen Pharma Ltd. Ordinary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00GFCC622
XNAS · usd
43.50▼ 0.31 (-0.72%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close43.82
Day's Range42.50 – 44.72
52-Week Range15.86 – 50.81
Volume418.4K
Avg Volume856.0K
Share Statistics
Shares Outstanding
Employees291
ExchangeXNAS
Listed2017-05-04
Share count as of July 28, 2026
Loading Income Statement…
Key questions about UroGen Pharma Ltd. Ordinary Shares (URGN)
What is UroGen Pharma Ltd. Ordinary Shares's Market Cap?
UroGen Pharma Ltd. Ordinary Shares's Market Cap is $2.1B, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's Enterprise Value?
UroGen Pharma Ltd. Ordinary Shares's Enterprise Value is $2.2B, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's Price / Sales?
UroGen Pharma Ltd. Ordinary Shares's Price / Sales is 11.3×, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's EV / Revenue?
UroGen Pharma Ltd. Ordinary Shares's EV / Revenue is 11.7×, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's EV / EBITDA?
UroGen Pharma Ltd. Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's Revenue (TTM)?
UroGen Pharma Ltd. Ordinary Shares's Revenue (TTM) is $188.7M, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's Net Income (TTM)?
UroGen Pharma Ltd. Ordinary Shares's Net Income (TTM) is -$97.6M, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's EBITDA?
UroGen Pharma Ltd. Ordinary Shares's EBITDA is -$66.3M, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's Diluted EPS (TTM)?
UroGen Pharma Ltd. Ordinary Shares's Diluted EPS (TTM) is -2.00, based on as-reported figures from SEC (XBRL) filings.
What is UroGen Pharma Ltd. Ordinary Shares's EBITDA Margin?
UroGen Pharma Ltd. Ordinary Shares's EBITDA Margin is -35.2%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+199.2%+151.6%+54.0%+9.0%
Cost of revenue
Gross profit
% of revenue90.9%91.9%91.3%88.1%
Operating expenses:
Research and development expenses
Selling, general and administrative expenses
Operating income (loss)
% of revenue0.2%-39.8%-50.5%-99.7%
Financing on prepaid forward obligation
Interest expense on long-term debt
Interest and other income, net
Loss before income taxes
Income tax expense
Net loss
% of revenue-19.8%-46.3%-69.7%-121.3%
Net loss
% of revenue-19.8%-46.3%-69.7%-121.3%
Net loss per ordinary share - basic and diluted (in dollars per share)